Skip Navigation

Lotus Reported Unaudited March Revenues of NT$1,151 million

10 April 2024

Taipei, Taiwan, April 10, 2024 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, has disclosed its unaudited consolidated revenue for March 2024, reaching NT$1,151 million.

In March, the Asian markets saw recovery in revenue after Chinese New Year holidays from previous month in Taiwan and Korea.  The Group’s Asian revenues grew approximately 14% versus the same period prior year.  However, as expected, the US revenues were less than the prior year, driven by the replenishment timing difference of Lenalidomide and Buprenorphine / Naloxone.

Lotus has achieved 1Q24 revenue of NT$4,198 million, down 7% YoY, primarily resulted from the absence of the lenalidomide 2.5 and 20 mg launch stock in 1Q24.  On the other hand, the revenue from products in export markets outside of the US demonstrated an almost 100% YoY growth, highlighting Lotus’ effort to continue expanding its market outreach.  

Looking ahead, Lotus anticipates a significant increase in the Lenalidomide business for 2024 compared to the previous year.


About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.

Media Inquiries:

Yu-ying Yang, Associate Director, Cooperate communication

+886 2 2700 5908